Top

Annals of Hematology

Published in:

01-03-2007 | Letter to the Editor

Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome

Authors: P. R. J. Ames, C. Tommasino, G. Fossati, G. Scenna, V. Brancaccio, F. Ferrara

Published in: Annals of Hematology | Issue 3/2007

Excerpt

Dear Editor …

Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311PubMedCrossRef

Cuadrado MJ, Mujic F, Munoz E, Khamashta MA, Hughes GRV (1997) Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis 56:194–196PubMedCrossRef

Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB (2004) The efficacy and safety of B cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopaenic purpura. Br J Haematol 125:232–239PubMedCrossRef

Youinou P, Reneaudineau Y (2004) The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases. Thromb Res 114:363–369PubMedCrossRef

Greaves M, Cohen H, MacHin SJ, Mackie I (2000) Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 109:704–715PubMedCrossRef

Braendstrup P, Bjerrum OW, Nielsen OJ et al (2005) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 78:275–280PubMedCrossRef

Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA (2006) Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 33:355–357PubMed

Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Aguirre C (2004) Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica 89:ECR34PubMed

Ahn ER, Lander G, Bidot CJ, Jy W, Ahn YS (2005) Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy. Am J Hematol 78:127–129PubMedCrossRef

10.

Harner KC, Jackson LW, Drabick JJ (2004) Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren’s syndrome. Rheumatology 43:1309–1310PubMedCrossRef

11.

Trappe R, Loew A, Thuss-Patience P, Dorken B, Riess H (2006) Successful treatment of thrombocytopenia in primary antiphospholipid syndrome with the anti-CD20 antibody rituximab-monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann Hematol 85:134–135PubMedCrossRef

12.

Weide R, Heymanns J, Pandorf A, Koppler H (2003) Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 12:779–782PubMedCrossRef

13.

Delgado Alves J, Inanc M, Diz-Kucukkaya R, Grima B, Soromenho F, Isenberg DA (2004) Thrombotic risk in patients submitted to splenectomy for systemic lupus erythematosus and antiphospholipid antibody syndrome-related thrombocytopenia. Eur J Intern Med 15:162–167PubMedCrossRef

14.

Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, Turgut M, Keskin H, Nalcaci M, Inanc M (2001) Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 98:1760–1764PubMedCrossRef

15.

Ames PRJ, Orefice G, Brancaccio V (1995) Reversal of thrombocytopenia following oral anticoagulation in two patients with primary antiphospholipid syndrome. Lupus 4:491–493PubMed

Title: Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome
Authors: P. R. J. Ames
C. Tommasino
G. Fossati
G. Scenna
V. Brancaccio
F. Ferrara
Publication date: 01-03-2007
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 3/2007
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-006-0226-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2007

Pure red cell aplasia in a patient of chronic granulocyte leukemia associated with imatinib

Genetic variation of FUT2 in a Ghanaian population: identification of four novel mutations and inference of balancing selection

Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology

Intensive blood transfusion support in acquired hemophilia A

Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates

Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials